 |
6 Diseases |  |
10 Trials |
|
10 Trials |  |
617 News |  |
| «12345678» |
- || celecoxib oral / Generic mfg.
Clinical, Journal: The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. (Pubmed Central) - Feb 15, 2022
The integration of new treatments into clinical practice should be informed by the potential for benefit relative to established therapies, as well as by the characteristics and preferences of individual patients.
- | Journal: New Anti-CGRP Medications in the Treatment of Vestibular Migraine. (Pubmed Central) - Feb 15, 2022
Results demonstrated a trend toward improvement, suggesting that the CGRP medications appear to be a decent treatment option for VM. A prospective study evaluating CGRP medications in patients with VM would provide further information about this treatment option.
- | Trudhesa (dihydroergotamine mesylate intranasal) / Impel NeuroPharma
Journal: A new dihydroergotamine nasal spray (Trudhesa) for migraine. (Pubmed Central) - Feb 8, 2022
A prospective study evaluating CGRP medications in patients with VM would provide further information about this treatment option. No abstract available
- |||||| Ubrelvy (ubrogepant) / AbbVie
Enrollment open, Adverse events: Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) (clinicaltrials.gov) - Feb 2, 2022
P3, N=1059, Recruiting, Sponsor: Allergan
No abstract available Not yet recruiting --> Recruiting
- | Ubrelvy (ubrogepant) / AbbVie
New P4 trial: ATOM: Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine (clinicaltrials.gov) - Jan 27, 2022
P4, N=645, Not yet recruiting, Sponsor: Messoud Ashina, MD
- | Ubrelvy (ubrogepant) / AbbVie, Reyvow (lasmiditan) / Eli Lilly, Daiichi Sankyo, Nurtec ODT (rimegepant ODT) / Portage, Pfizer
Retrospective data, Journal: Comparative efficacy and safety of rimegepant, ubrogepant and lasmiditan for acute treatment of migraine: a network meta-analysis. (Pubmed Central) - Jan 27, 2022
Lasmiditan, rimegepant, and ubrogepant all performed significantly better than placebo with respect to pain freedom and pain relief. Efficacy results were similar for rimegepant and lasmiditan with rimegepant having higher rates of pain freedom and relief than lower doses of lasmiditan, while somnolence and dizziness outcomes were lower for rimegepant than higher doses of lasmiditan.
- | Ubrelvy (ubrogepant) / AbbVie
Journal: Phase-Transfer-Catalyzed Asymmetric Annulations of Alkyl Dihalides with Oxindoles: Unified Access to Chiral Spirocarbocyclic Oxindoles. (Pubmed Central) - Jan 19, 2022
A general phase-transfer-catalyzed asymmetric (n+1) (n = 4 or 5) annulation reaction, featuring the direct coupling of simple oxindoles with alkyl dihalides that are allylic/benzylic and non-allylic/benzylic, has been developed to provide previously inaccessible cyclopentane- and cyclohexane-fused spirooxindole scaffolds with high yields and enantioselectivities (88-95% ee). Along with a broad scope and mild conditions, the new protocol also enables a two-step and gram-scale synthesis of the core of the drug ubrogepant.
- || Ubrelvy (ubrogepant) / AbbVie
Clinical, Journal: Critique of the analysis of the time course for the antimigraine effect of ubrogepant 50 mg. Clinical relevance versus statistical significance. (Pubmed Central) - Jan 18, 2022
Along with a broad scope and mild conditions, the new protocol also enables a two-step and gram-scale synthesis of the core of the drug ubrogepant. No abstract available
- || sumatriptan succinate / Generic mfg.
Clinical, Retrospective data, Review, Journal: Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis. (Pubmed Central) - Jan 12, 2022
For pain freedom or pain relief at 2 hours after the dose, lasmiditan, rimegepant, and ubrogepant were associated with higher ORs compared with placebo but lower ORs compared with most triptans. However, the lack of cardiovascular risks for these new classes of migraine-specific treatments may offer an alternative to triptans.
- || Ubrelvy (ubrogepant) / AbbVie, Reyvow (lasmiditan) / Eli Lilly, Daiichi Sankyo
Clinical, Journal: Newer Horizon for Treatment of Acute Attack of Migraine: Lasmiditan and Ubrogepant. (Pubmed Central) - Jan 11, 2022
The approval was supported by two pivotal phase-3, randomized, double-blind, placebo-controlled trials (ACHIEVE I and ACHIEVE II) that evaluated the efficacy, safety, tolerability. Hopefully, these two drugs may soon be a new addition to the mounting armory of drugs against migraine and may fulfill a substantial unmet need.
- || Ubrelvy (ubrogepant) / AbbVie
Clinical, Retrospective data, Journal: Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis. (Pubmed Central) - Dec 29, 2021
Hopefully, these two drugs may soon be a new addition to the mounting armory of drugs against migraine and may fulfill a substantial unmet need. Ubrogepant efficacy and tolerability did not differ for the acute treatment of migraine in participants classified as triptan responders, triptan-insufficient responders, and triptan-naïve based on their historical experience with triptans.
- || Ubrelvy (ubrogepant) / AbbVie
Clinical, Journal: Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications. (Pubmed Central) - Dec 18, 2021
P3
Efficacy was demonstrated out to 48 h, providing evidence of the long-lasting effect of ubrogepant. This evaluation supports the role of examining the entire time course of effect to understand fully the utility of an acute treatment for migraine.Trial registration: ACHIEVE I (ClinicalTrials.gov, NCT02828020) and ACHIEVE II (ClinicalTrials.gov, NCT02867709).
- | Journal: Migraine therapeutics differentially modulate the CGRP pathway. (Pubmed Central) - Dec 18, 2021
The therapeutic effect of agents targeting the CGRP ligand versus receptor for migraine prevention (antibodies) or acute treatment (gepants) may involve distinct mechanisms of action. These findings suggest that differing mechanisms could affect efficacy, safety, and/or tolerability in migraine patients.
- || Ubrelvy (ubrogepant) / AbbVie
Clinical, Journal, Real-world evidence: Real-world efficacy, tolerability, and safety of ubrogepant. (Pubmed Central) - Dec 16, 2021
Adverse event rates were higher than reported in clinical trials. Further studies are needed to confirm these findings and to evaluate the long-term efficacy and safety of ubrogepant.
- || Ubrelvy (ubrogepant) / AbbVie
Clinical, P1 data, PK/PD data, Journal: Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study. (Pubmed Central) - Dec 16, 2021
Further studies are needed to confirm these findings and to evaluate the long-term efficacy and safety of ubrogepant. The PK profile of ubrogepant was not significantly changed and no safety concerns were identified when ubrogepant was coadministered with erenumab or galcanezumab.
- ||| Ubrelvy (ubrogepant) / AbbVie
Clinical, P3 data, Journal: Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II. (Pubmed Central) - Dec 16, 2021
P3
The safety and efficacy of ubrogepant for the acute treatment of a single migraine attack did not differ by the presence of major cardiovascular risk factors. No evidence of increased treatment-emergent adverse events or cardiac system organ class adverse events with ≥2 major cardiovascular risk factors and no safety concerns were identified.Trial Registration: ACHIEVE I ClinicalTrials.gov number, NCT02828020; ACHIEVE II ClinicalTrials.gov number, NCT02867709.
- | Reyvow (lasmiditan) / Eli Lilly, Daiichi Sankyo
Journal, HEOR: Budget impact of lasmiditan for the acute treatment of migraine in the United States. (Pubmed Central) - Dec 16, 2021
Milev and Sun are employed by Evidera, which received funding from Eli Lilly and Company for work on this project. Pohl, Mason, Njuguna, and Loo are employees and stockholders of Eli Lilly and Company.
- |||||| Ubrelvy (ubrogepant) / AbbVie, Qulipta (atogepant) / AbbVie
New trial, Adverse events: Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy (clinicaltrials.gov) - Dec 14, 2021
P=N/A, N=1120, Not yet recruiting, Sponsor: Allergan
- || Reyvow (lasmiditan) / Eli Lilly, Daiichi Sankyo
Clinical, Review, Journal: Safety and Risk of Medication Overuse Headache in Lasmiditan and Second-Generation Gepants: A Rapid Review. (Pubmed Central) - Dec 2, 2021
All three medications are now prescribed in a real-world setting, and an adequate level of knowledge is the starting point for rational use. In this rapid systematic review, we have established what is known about lasmiditan, ubrogepant and rimegepant, highlighting the most relevant safety aspects available from published studies and speculating about their risk of MOH.
- Ubrelvy (ubrogepant) / AbbVie
Assessment of Ubrogepant Use Within a Veteran Affairs Community-Based Outpatient Pharmacy ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_3586;
- Ubrelvy (ubrogepant) / AbbVie, Nurtec ODT (rimegepant ODT) / Portage, Pfizer
Evaluation of Safety and Efficacy Studies of New Calcitonin Gene-related Peptide Antagonists (rimegepant and Ubrogepant) for the Acute Treatment of Migraine ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_2480;
- || Ubrelvy (ubrogepant) / AbbVie, Nurtec ODT (rimegepant ODT) / Portage, Pfizer
Review, Journal: Unmet needs in the acute treatment of migraine attacks and the emerging role of calcitonin gene-related peptide receptor antagonists: An integrative review. (Pubmed Central) - Nov 29, 2021
The availability and use of CGRP receptor antagonists may help reduce the extent of unmet needs in the treatment of migraine attacks, resulting in more patients receiving treatment and better outcomes for people with migraine. Nurse practitioners are well positioned to increase rates of migraine diagnosis/treatment (another key unmet need), using consensus guidelines to guide their approach.
- |||||||||| Ubrelvy (ubrogepant) / AbbVie
New P3 trial: Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17) (clinicaltrials.gov) - Nov 18, 2021
P3, N=1200, Not yet recruiting, Sponsor: Allergan
- |||||||||| Ubrelvy (ubrogepant) / AbbVie
New P3 trial, Adverse events: Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) (clinicaltrials.gov) - Nov 18, 2021
P3, N=1059, Not yet recruiting, Sponsor: Allergan
- || Reyvow (lasmiditan) / Eli Lilly, Daiichi Sankyo
Review, Journal: Lasmiditan: Acute Migraine Treatment Without Vasoconstriction. A Review. (Pubmed Central) - Nov 10, 2021
Lasmiditan is an oral tablet drug that is used for acute migraine abortive treatment and data suggest that it does not induce vasoconstriction, a common side effect often observed with the current first-line abortive migraine treatment drug class, triptans. This is especially important in acute migraine patients with cardiovascular risk factors in which triptan use is contraindicated.
- | Nurtec ODT (rimegepant ODT) / Portage
Journal: Rimegepant: acute treatment for migraine headaches. (Pubmed Central) - Oct 30, 2021
Rimegepant is one of these newly approved agents for acute migraine treatment in adults with or without aura. Rimegepant has been found to decrease pain and symptoms associated with migraine attacks and is generally well-tolerated.
- | Ubrelvy (ubrogepant) / AbbVie
Preclinical, Journal: Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache. (Pubmed Central) - Oct 27, 2021
These studies suggest ubrogepant may offer an effective acute treatment of migraine without risk of medication overuse headache. Trial Registration Number: Not applicable.
- telcagepant (MK-0974) / Merck (MSD)
[VIRTUAL] ADVANCING CALCITONIN GENE-RELATED PEPTIDE RECEPTOR (CGRP) ANTAGONISTS USING QUANTITATIVE SYSTEMS TOXICOLOGY MODELING TO CHARACTERIZE NEXT-IN-CLASS COMPOUNDS COMPARED TO THE HEPATOTOXIC FIRST IN CLASS TELCAGEPANT () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1425;
The four next-in-class compounds did not show the same signal for liver safety concerns as telcagepant . Subsequent clinical trials have validated these results, and both rimegepant and ubrogepant have been approved by the FDA with no warning for hepatotoxicity .
- || Ubrelvy (ubrogepant) / AbbVie, Reyvow (lasmiditan) / Eli Lilly, Daiichi Sankyo, Nurtec ODT (rimegepant ODT) / Portage
Clinical, Journal: A Framework for Estimating the Eligible Patient Population for New Migraine Acute Therapies in the United States. (Pubmed Central) - Oct 13, 2021
The framework developed in this study is intended to facilitate estimating the eligible patient population in assessments of costs of new acute therapies. Such assessments should also consider recommendations that patients have access to multiple types of acute therapies, which may yield savings from reduced medication-overuse headache (MOH), progression to chronic migraine, and urgent-care costs.
- Supraorbital Neuromodulation For Intractable Chronic Migraines (Exhibit Hall) - Sep 25, 2021 - Abstract #ASA2021ASA_4484;
She tried numerous pharmacologic agents including galcanezumab, erenumab, nortriptyline, amitriptyline, gabapentin, aripiprazole, duloxetine, topiramax, rizatriptan, ubrogepant, sumatriptan and procedural therapy including Botox with no resolution of symptoms. Chronic pain management was consulted, and she underwent a successful bilateral supraorbital nerve stimulator trial with 80% improvement in symptoms followed by permanent placement of stimulator leads and pulse generator.
- ||| Ubrelvy (ubrogepant) / AbbVie
Clinical, P3 data, Journal: Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II. (Pubmed Central) - Sep 22, 2021
A significantly higher proportion of participants treated with ubrogepant were able to function normally, were satisfied with the study medication, and reported clinically meaningful improvement compared with those receiving placebo. The results reinforce the potential benefits of ubrogepant on patient-centered outcomes in the acute treatment of migraine.
- || Ubrelvy (ubrogepant) / AbbVie
Clinical, PK/PD data, Journal: Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans. (Pubmed Central) - Sep 22, 2021
Coadministration of ubrogepant with sumatriptan was well tolerated in healthy participants in the Phase 1 study, and coadministration of ubrogepant with triptans was well tolerated in participants with migraine in the Phase 3 trials. No new safety concerns for ubrogepant were identified across all trials.
- || Ubrelvy (ubrogepant) / AbbVie, Nurtec ODT (rimegepant ODT) / Portage
Review, Journal: CGRP and migraine; from bench to bedside. (Pubmed Central) - Sep 16, 2021
Here I will provide a historical overview of the long path that led to their successful development. In addition, I will discuss aspects on the biology of CGRP signalling, the role of CGRP in migraine headache, the efficacy of CGRP targeted treatment, and synthesize what currently is known about the role of CGRP in the trigeminovascular system.
- Ubrelvy (ubrogepant) / AbbVie
Ubrogepant Was Safe and Well Tolerated in the Acute Treatment of Perimenstrual Migraine Attacks () - Sep 15, 2021 - Abstract #PAINWeek2021PAINWeek_97;
Treatment-related adverse events were reported by 12/137 (8.8%) and 18/141 (12.8%) in the ubrogepant 50 mg and 100 mg subgroups of participants who experienced a pmM, respectively. Conclusion : In this randomized 52-week extension trial, the efficacy of ubrogepant for the treatment of pmM was comparable to that observed for non-pmM.
- Ubrelvy (ubrogepant) / AbbVie
Ubrogepant Treatment When Pain Is Mild Increases the Likelihood of Achieving Pain Freedom in Participants Who Treated Migraine Attacks of Mild and Moderate or Severe Pain () - Sep 15, 2021 - Abstract #PAINWeek2021PAINWeek_96;
P3
Conclusion : These data indicate that treatment of migraine attacks with ubrogepant 50mg or 100mg when pain is mild versus moderate or severe significantly increases the odds of achieving pain freedom at 2 hours. The findings in this subgroup, which treated attacks of both mild pain and moderate or severe pain, confirm the results that were observed in the overall trial population and further support the recommendation to treat early when pain is mild.
- Patient clinical characteristics and treatment utilization among patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibody and novel acute medication () - Sep 15, 2021 - Abstract #PAINWeek2021PAINWeek_60;
The most common comorbid conditions were anxiety, depression, sleep disorder, hypertension, gastroesophageal reflux disease, sinusitis, and fatigue. Understanding the demographic and clinical characteristics of patients who initiate a self-injectable CGRP and novel acute medication for migraine as well as treatment utilization may provide valuable insight about treatment selection for migraine to clinicians and other healthcare decision makers.
- Ubrelvy (ubrogepant) / AbbVie
COmbining UbRogepAnt and preventives for miGrainE (COURAGE) study using the Migraine Buddy application: A novel, entirely remote design for collecting real-world evidence () - Sep 15, 2021 - Abstract #PAINWeek2021PAINWeek_21;
Purpose : To describe the design and interim findings from the COURAGE study, a novel, web-based mobile application (app)-based methodology to evaluate real-world effectiveness of ubrogepant when used with an anti-calcitonin gene–related peptide (CGRP) monoclonal antibody preventive (mAb) or with onabotulinumtoxinA (onabotA) or with both...The majority of these participants reported use of ubrogepant 100 mg (59.6% [115/193]) and erenumab was the most commonly used CGRP mAb (44.6% [86/193])...This entirely remote design provides a unique opportunity to continue to understand treatment value and practice patterns while keeping patients and health care providers safe during the current COVID-19 pandemic. These findings suggest that ubrogepant is effective when used in combination with a CGRP mAb; final data will help to inform practicing clinicians to optimize migraine treatment in their practices.
- || Ubrelvy (ubrogepant) / AbbVie, Qulipta (atogepant) / AbbVie
Trial completion, Adverse events: Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine (clinicaltrials.gov) - Sep 14, 2021
P1b, N=26, Completed, Sponsor: Allergan
These findings suggest that ubrogepant is effective when used in combination with a CGRP mAb; final data will help to inform practicing clinicians to optimize migraine treatment in their practices. Active, not recruiting --> Completed
- | Journal: Novel Therapies in Acute Migraine Management: Small-Molecule Calcitonin Gene-Receptor Antagonists and Serotonin 1F Receptor Agonist. (Pubmed Central) - Aug 21, 2021
Based on available data, ubrogepant, rimegepant, and lasmiditan should be reserved as second-line therapy and may be safe in patients with cardiovascular risk. Lasmiditan's adverse effect profile may limit its use.
- |||||| Ubrelvy (ubrogepant) / AbbVie
Enrollment open, Trial completion date, Trial primary completion date: Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants (clinicaltrials.gov) - Aug 18, 2021
P3, N=600, Recruiting, Sponsor: Allergan
Lasmiditan's adverse effect profile may limit its use. Active, not recruiting --> Recruiting | Trial completion date: Dec 2021 --> Jul 2022 | Trial primary completion date: Dec 2021 --> Jul 2022
- Ubrelvy (ubrogepant) / AbbVie, Nurtec ODT (rimegepant ODT) / Portage
[VIRTUAL] To probe the binding interactions between two FDA approved migraine drugs (Ubrogepant and Rimegepant) and calcitonin-gene related peptide receptor (CGRPR) using molecular dynamics simulations (Room: Zoom Room 35) - Aug 13, 2021 - Abstract #ACSFall2021ACS_Fall_3185;
The ubrogepant and rimegepant both contact A70, M42, and R119 of the receptor, while olcegepant does not. The results of this study elucidate the interactions in the binding pocket of CGRP receptor and can assist in further development for orally available antagonists of the CGRP receptor.
- ||||| Ubrelvy (ubrogepant) / AbbVie
Enrollment closed: Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants (clinicaltrials.gov) - Aug 12, 2021
P3, N=600, Active, not recruiting, Sponsor: Allergan
The results of this study elucidate the interactions in the binding pocket of CGRP receptor and can assist in further development for orally available antagonists of the CGRP receptor. Recruiting --> Active, not recruiting
- |||| Ubrelvy (ubrogepant) / AbbVie, Nurtec ODT (rimegepant ODT) / Portage
Clinical: Biohaven's Nurtec ODT outmuscles AbbVie's Ubrelvy in gaining new migraine patients following key FDA nod https://t.co/ckC7nvJjFd (Twitter) - Aug 9, 2021
- || Ubrelvy (ubrogepant) / AbbVie
Clinical, P2b data, Journal: Making Better Dose Decisions: Using Exposure-Response Modeling to Integrate Efficacy Outcome of Two Phase 2b Clinical Trials of Ubrogepant for Migraine Treatment. (Pubmed Central) - Aug 8, 2021
Model-based simulations predict that a dose of 25 mg or higher is likely to achieve significantly better efficacy than placebo with desirable efficacy levels. The understanding of E-R helped support the dose selection for the Phase III clinical trials.
- || Ubrelvy (ubrogepant) / AbbVie
Clinical, Journal: Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males. (Pubmed Central) - Aug 8, 2021
Overall, there was no evidence of ubrogepant-associated hepatotoxicity with daily doses up to 400 mg for 10 days or with daily ubrogepant 150 mg for 28 days. Supratherapeutic dosing is a useful strategy for characterizing hepatic safety in early drug development.
- || Ubrelvy (ubrogepant) / AbbVie
Retrospective data, Review, Journal: Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials. (Pubmed Central) - Aug 7, 2021
Short-term use of ubrogepant was not related to an increased risk for adverse events. Further studies are needed to evaluate efficacy and safety for long-term use and in specific subgroups of patients.
- | Ubrelvy (ubrogepant) / AbbVie, Nurtec ODT (rimegepant ODT) / Portage
FDA event, Journal: To Probe the Binding Interactions between Two FDA Approved Migraine Drugs (Ubrogepant and Rimegepant) and Calcitonin-Gene Related Peptide Receptor (CGRPR) Using Molecular Dynamics Simulations. (Pubmed Central) - Aug 4, 2021
The ubrogepant and rimegepant both contact A70 and M42 of the receptor, while olcegepant does not. The results of this study elucidate the interactions in the binding pocket of CGRP receptor and can assist in further development for orally available antagonists of the CGRP receptor.
- | Journal: Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants. (Pubmed Central) - Jul 30, 2021
Multiple clinical trials of the CGRP monoclonal antibodies and gepants, and now some open-label long-term extension data, established their efficacy, safety, and tolerability. In this chapter, we summarize the major clinical trials, pharmacokinetic insights, safety and tolerability profiles, and real-world data (if available) of the CGRP monoclonal antibodies and gepants.
- || Ubrelvy (ubrogepant) / AbbVie
Clinical, Journal: Mechanistic Investigations Support Liver Safety of Ubrogepant. (Pubmed Central) - Jul 23, 2021
In contrast, DILIsym predicted no hepatotoxicity during treatment with ubrogepant, even at daily doses up to 1000 mg (10-fold higher than the proposed clinical dose of 100 mg). These predictions are consistent with clinical trial experience showing that ubrogepant has lower potential to cause hepatotoxicity than has been observed with telcagepant and MK-3207.
- | Ubrelvy (ubrogepant) / AbbVie, Reyvow (lasmiditan) / Eli Lilly, Nurtec ODT (rimegepant ODT) / Portage
Journal: ICER's assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine. (Pubmed Central) - Jul 17, 2021
DISCLOSURES: No funding supported the writing of this commentary. The authors have nothing to disclose.